ix-01
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT01994083)
Timeline
Indications
Mechanism of action
- Oxytocin receptorANTAGONIST
OXTR antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ix-01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03055806 | Phase 2 | Feb 28, 2017 | Ixchelsis Limited |
| NCT02962531 | Phase 1 | Nov 1, 2016 | Ixchelsis Limited |
| NCT02792647 | Phase 1 | May 1, 2016 | Hammersmith Medicines Research, Ixchelsis Limited |
| NCT02232425 | Phase 2 | Sep 1, 2014 | ICON, Ixchelsis Limited, New England Research Institutes, Novotech, PHT Corporation |
| NCT02139826 | Phase 1 | May 1, 2014 | Ixchelsis Limited |
| NCT01994083 | Phase 1 | Nov 1, 2013 | Ixchelsis Limited |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ixchelsis Limited | For profit | 6 | 6 | 2 | 2013 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2016 |
| ICON | For profit | 1 | 0 | 1 | 2014 |
| New England Research Institutes | For profit | 1 | 0 | 1 | 2014 |
| Novotech | For profit | 1 | 0 | 1 | 2014 |
| PHT Corporation | For profit | 1 | 0 | 1 | 2014 |
6 organizations
Page 1 / 1